Browsing by author "Flux, Glenn"
Now showing items 1-10 of 10
-
Differentiated thyroid cancer patients potentially benefitting from postoperative I-131 therapy: a review of the literature of the past decade.
Verburg, FA; Flux, G; Giovanella, L; van Nostrand, D; Muylle, K; et al. (SPRINGER, 2019-10-15)BACKGROUND: Since the last major review of literature on the benefit of I-131 therapy, the continued debate on postoperative radioiodine treatment (RIT) in differentiated thyroid carcinoma (DTC) has led to a number of ... -
Dosimetry-based treatment for Graves' disease.
Hyer, SL; Pratt, B; Gray, M; Chittenden, S; Du, Y; et al. (2018-06)Objective The aim of this retrospective study was to assess the long-term outcome of a personalized dosimetry approach in Graves' disease aiming to render patients euthyroid from a planned thyroid absorbed dose of ... -
Dosimetry-based treatment planning for molecular radiotherapy: a summary of the 2017 report from the Internal Dosimetry Task Force.
Stokke, C; Gabiña, PM; Solný, P; Cicone, F; Sandström, M; et al. (2017-11-21)BACKGROUND:The European directive on basic safety standards (Council directive 2013/59 Euratom) mandates dosimetry-based treatment planning for radiopharmaceutical therapies. The directive comes into operation February ... -
EFOMP policy statement NO. 19: Dosimetry in nuclear medicine therapy - Molecular radiotherapy.
Sjögreen-Gleisner, K; Flux, G; Bacher, K; Chiesa, C; de Nijs, R; et al. (ELSEVIER SCI LTD, 2023-12-01)The European Council Directive 2013/59/Euratom (BSS Directive) includes optimisation of treatment with radiotherapeutic procedures based on patient dosimetry and verification of the absorbed doses delivered. The present ... -
Leonidas D. Marinelli: Cold War Scientist.
Godfrey, JM; Flux, GD (RADIATION RESEARCH SOC, 2023-02-01) -
Opportunities for research in molecular radiotherapy.
Flux, GD; O'Sullivan, J; Gaze, MN; Prise, KM (2017-03)Cancer has been treated with radiopharmaceuticals for 80 years. A recent National Cancer Research Institute report from the Clinical and Translational Radiotherapy Research Working Group reviews the current status of ... -
Second primary malignancies induced by radioactive iodine treatment of differentiated thyroid carcinoma - a critical review and evaluation of the existing evidence.
Reinecke, MJ; Ahlers, G; Burchert, A; Eilsberger, F; Flux, GD; et al. (SPRINGER, 2022-03-23)PURPOSE: Concern is growing about long-term side effects of differentiated thyroid cancer treatment, most notably radioactive iodine (RAI) therapy. However, published studies on the subject have had heterogeneous cohorts ... -
The potential of <sup>223</sup>Ra and <sup>18</sup>F-fluoride imaging to predict bone lesion response to treatment with <sup>223</sup>Ra-dichloride in castration-resistant prostate cancer.
Murray, I; Chittenden, SJ; Denis-Bacelar, AM; Hindorf, C; Parker, CC; et al. (2017-10)Purpose The aims of this study were to calculate bone lesion absorbed doses resulting from a weight-based administration of 223 Ra-dichloride, to assess the relationship between those doses and corresponding 18 F-fluoride ... -
Variations in the practice of molecular radiotherapy and implementation of dosimetry: results from a European survey.
Sjögreen Gleisner, K; Spezi, E; Solny, P; Gabina, PM; Cicone, F; et al. (2017-12-04)BACKGROUND:Currently, the implementation of dosimetry in molecular radiotherapy (MRT) is not well investigated, and in view of the Council Directive (2013/59/Euratom), there is a need to understand the current availability ... -
Whole-remnant and maximum-voxel SPECT/CT dosimetry in <sup>131</sup>I-NaI treatments of differentiated thyroid cancer.
Mínguez, P; Flux, G; Genollá, J; Delgado, A; Rodeño, E; et al. (2016-10)Purpose To investigate the possible differences between SPECT/CT based whole-remnant and maximum-voxel dosimetry in patients receiving radio-iodine ablation treatment of differentiated thyroid cancer (DTC).Methods Eighteen ...